NicOx Press Releases

	NicOx press releases (2008-2009)


	Archives (from 1996 up to date):
	Select a year and / or Keyword.. GO



	Title		Date

	• NicOx announces EMEA validation of naproxcinod MAA submission		22/01/2010

	• NicOx and TOPIGEN Pharmaceuticals terminate collaboration following the acquisition of TOPIGEN by Pharmaxis		12/01/2010

	• NicOx submits naproxcinod MAA to the EMEA		22/12/2009

	• NicOx announces FDA accepts naproxcinod NDA for filing		18/11/2009

	• NicOx announces NCX 6560 meets primary and secondary objectives in first-in-man study		13/11/2009

	• Report of NicOx’s financial results for the first three quarters of 2009		22/10/2009

	• NicOx presents 26 week naproxcinod efficacy data at American College of Rheumatology		20/10/2009

	• NicOx submits New Drug Application (NDA) for naproxcinod to the US FDA		25/09/2009

	• Important data for NicOx’ naproxcinod published in the American Journal of Cardiology		22/09/2009

	• NicOx makes three scientific presentations at the 2009 World Congress on Osteoarthritis		14/09/2009

	• NicOx reacquires rights to PF-03187207 for glaucoma from Pfizer		06/08/2009

	• NicOx first half 2009 financial results: naproxcinod nearing regulatory submissions in US and Europe		29/07/2009

	• NicOx: additional 24 hour blood pressure results for naproxcinod presented at the European Meeting on Hypertension		15/06/2009

	• NicOx presents naproxcinod results in several posters at EULAR		12/06/2009

	• NicOx publishes results of the ZEST phase 2 study for naproxcinod		09/06/2009

	• NicOx presents phase 3 quality of life data for naproxcinod at ISPOR		19/05/2009

	• NicOx reports first quarter 2009 financial results		13/05/2009

	• Analyses of phase 3 blood pressure data for NicOx’ naproxcinod presented at ASH		07/05/2009

	• NicOx co-presents four posters on PF 03187207 for glaucoma at ARVO with Pfizer Inc		05/05/2009

	• NicOx acquires Nitromed’s NO-donating patents		23/04/2009

	• New analyses of phase 3 data for NicOx’ naproxcinod presented at the American College of Cardiology (ACC) Annual Meeting		31/03/2009

	• NicOx initiates proof-of-principle clinical study for NCX 6560		18/03/2009

	• Financial results for full year 2008: NicOx in a unique position to deliver significant shareholder value		26/02/2009



	Click here to be added to our mailing list



	Printable version



	Archives (from 1996 up to date) GO


	For more information :

	NicOx: Karl Hanks, Director of investor relations and Corporate Communications Tel. +33 (0)4 97 24 53 42 / hanks@nicox.com


	Media in the United States - FD: Robert Stanislaro, Tel +1 212 850 5657 / robert.stanislaro@fd.com Irma Gomez-Dib, Tel +1 212 850 5761 / irma.gomez-dib@fd.com Media in Europe - Citigate Dewe: Nina Enegren, Tel +44 (0)207 282 1050 • nina.enegren@citigatedr.co.uk David Dible, •david.dible@citigatedr.co.uk